Instrumentl eFile Render
Object ID: 202233189349301248 - Rendered 2024-05-07
TIN: 91-1157127
Form
990
Department of the Treasury
Internal Revenue Service
Return of Organization Exempt From Income Tax
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)
Do not enter social security numbers on this form as it may be made public.
Go to
www.irs.gov/Form990
for instructions and the latest information.
OMB No. 1545-0047
20
21
Open to Public Inspection
A
For the 2021 calendar year, or tax year beginning
01-01-2021
, and ending
12-31-2021
B
Check if applicable:
Address change
Name change
Initial return
Final return/terminated
Amended return
Application pending
C
Name of organization
PATH
Doing business as
Number and street (or P.O. box if mail is not delivered to street address)
2201 WESTLAKE AVENUE 200
Room/suite
City or town, state or province, country, and ZIP or foreign postal code
SEATTLE
,
WA
98121
D Employer identification number
91-1157127
E Telephone number
G
Gross receipts $
398,901,838
F
Name and address of principal officer:
KELLY PRIESTLEY
2201 WESTLAKE AVENUE 200
SEATTLE
,
WA
98121
I
Tax-exempt status:
501(c)(3)
501(c)
(
)
(insert no.)
4947(a)(1)
or
527
J
Website:
WWW.PATH.ORG
H(a)
Is this a group return for
subordinates?
Yes
No
H(b)
Are all subordinates
included?
Yes
No
If "No," attach a list. See instructions.
H(c)
Group exemption number
K
Form of organization:
Corporation
Trust
Association
Other
L
Year of formation:
1981
M
State of legal domicile:
WA
Part I
Summary
1
Briefly describe the organization’s mission or most significant activities:
SEE PART III, LINE 1.
2
Check this box
3
Number of voting members of the governing body (
Part VI
, line 1a)
........
3
16
4
Number of independent voting members of the governing body (
Part VI
, line 1b)
.....
4
16
5
Total number of individuals employed in calendar year 2021 (
Part V
, line 2a)
......
5
667
6
Total number of volunteers (estimate if necessary)
.............
6
0
7a
Total unrelated business revenue from
Part VIII
, column (C), line 12
........
7a
0
b
Net unrelated business taxable income from Form 990-T, Part I, line 11
.........
7b
0
Prior Year
Current Year
8
Contributions and grants (
Part VIII
, line 1h)
.........
287,454,383
333,068,959
9
Program service revenue (
Part VIII
, line 2g)
.........
0
0
10
Investment income (
Part VIII
, column (A), lines 3, 4, and 7d )
....
12,502,251
9,205,357
11
Other revenue (
Part VIII
, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)
1,030,112
843,270
12
Total revenue—add lines 8 through 11 (must equal
Part VIII
, column (A), line 12)
300,986,746
343,117,586
13
Grants and similar amounts paid (
Part IX
, column (A), lines 1–3 )
...
67,994,827
75,961,955
14
Benefits paid to or for members (
Part IX
, column (A), line 4)
.....
0
0
15
Salaries, other compensation, employee benefits (
Part IX
, column (A), lines 5–10)
132,096,396
135,407,327
16a
Professional fundraising fees (
Part IX
, column (A), line 11e)
.....
0
0
b
Total fundraising expenses (
Part IX
, column (D), line 25)
5,667,202
17
Other expenses (
Part IX
, column (A), lines 11a–11d, 11f–24e)
....
92,968,260
123,975,347
18
Total expenses. Add lines 13–17 (must equal
Part IX
, column (A), line 25)
293,059,483
335,344,629
19
Revenue less expenses. Subtract line 18 from line 12
.......
7,927,263
7,772,957
Beginning of Current Year
End of Year
20
Total assets (
Part X
, line 16)
.............
283,556,203
307,073,332
21
Total liabilities (
Part X
, line 26)
.............
234,982,056
253,115,813
22
Net assets or fund balances. Subtract line 21 from line 20
.....
48,574,147
53,957,519
Part II
Signature Block
Sign Here
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.
Signature of officer
Date
Type or print name and title
Paid Preparer Use Only
Print/Type preparer's name
Preparer's signature
Date
Check
if
self-employed
PTIN
Firm's name
Firm's EIN
Firm's address
Phone no.
May the IRS discuss this return with the preparer shown above? (see instructions)
..........
Yes
No
For Paperwork Reduction Act Notice, see the separate instructions.
Cat. No. 11282Y
Form
990
(2021)
Form 990 (2021)
Page
2
Part III
Statement of Program Service Accomplishments
Check if Schedule O contains a response or note to any line in this
Part III
..............
1
Briefly describe the organization’s mission:
PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O)
2
Did the organization undertake any significant program services during the year which were not listed on
the prior Form 990 or 990-EZ?
.....................
Yes
No
If "Yes," describe these new services on Schedule O.
3
Did the organization cease conducting, or make significant changes in how it conducts, any program
services?
...........................
Yes
No
If "Yes," describe these changes on Schedule O.
4
Describe the organization’s program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.
4a
(Code:
) (Expenses $
121,408,713
including grants of $
32,739,259
) (Revenue $
)
THE PROGRAMS & INNOVATION DIVISION BRINGS DEEP TECHNICAL EXPERTISE AND A ROBUST, COLLABORATIVE, AND INTERDISCIPLINARY APPROACH TO SUPPORT PATH COUNTRY PROGRAMS AND PARTNERS IN ADVANCING HEALTH EQUITY. WE FOCUS ON GENERATING ANALYTICAL INSIGHTS, TRANSLATING THEM INTO ADVOCACY AND ACTION, ADVANCING INCLUSIVE AND SUSTAINABLE INNOVATION, AND STRENGTHENING WORKFORCE SKILLS AND RESOURCES THAT SUPPORT INTEGRATED AND RESILIENT HEALTH SYSTEMS. OUR WORK COVERS DIGITAL TRANSFORMATION, PRODUCT DEVELOPMENT, MARKET SHAPING, EPIDEMIC PREPAREDNESS AND RESPONSE, AND MORE.(CONTINUED ON SCHEDULE O)CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2021, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE CATALYZED COUNTRY-LED DIGITAL HEALTH TRANSFORMATION. FOR EXAMPLE, WORK CONTINUED ON THE DATA USE PARTNERSHIP, A BILL & MELINDA GATES FOUNDATION-FUNDED PROJECT WHERE PATH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE ITS HEALTH INFORMATION SYSTEMS. THROUGH THIS PROJECT, THE GOVERNMENT ENDORSED A NEW HEALTH ENTERPRISE ARCHITECTURE, AN IMPORTANT STEP TO ENSURE ALIGNMENT OF THE COUNTRY'S DIGITAL SYSTEMS. IN ADDITION, THE PROJECT LAUNCHED AN IMPROVED E-LEARNING PLATFORM THAT STREAMLINES AND STANDARDIZES E-LEARNING MODULES TO MAKE IT EASIER TO TRACK HEALTH WORKER CREDENTIALS AND SCHOOL RECORDS.THE DATA USE ACCELERATION AND LEARNING PROJECT, ALSO FUNDED BY THE GATES FOUNDATION, CAPTURED LEARNINGS FROM FIVE COUNTRIES - BURKINA FASO, ETHIOPIA, MALAWI, SOUTH AFRICA, AND TANZANIA - TO DEVELOP A MODEL FOR DIGITAL TRANSFORMATION FOR DATA USE THAT BUILDS ON EXISTING FRAMEWORKS. THE INFORMATION WILL SUPPORT GOVERNMENTS, IMPLEMENTERS, POLICYMAKERS, AND FUNDERS AS THEY SHIFT THEIR FINANCING, GUIDANCE, AND PROGRAMMATIC APPROACHES TO IMPROVE THE USE OF DATA.BACKED BY A U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID) INVESTMENT OF UP TO $120 MILLION, DIGITAL SQUARE, A PATH-LED INITIATIVE, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES, WITH AN EMPHASIS ON COUNTRY-DRIVEN PRIORITIES.PATH, WITH U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FUNDING, IS LEADING THE OVERALL HEALTH INFORMATION SYSTEM SUPPORT COMPONENT OF THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) TECHNICAL ASSISTANCE PLATFORM THAT PARTNERS WITH COUNTRIES TO SUPPORT THEM IN BUILDING LASTING DIGITAL HEALTH CAPACITY. IN 2021, THE TEAM RECEIVED APPROVAL FOR OUR SECOND-YEAR WORK PLAN AND BUDGET, ENABLING WORK TO BEGIN ON STRENGTHENING HEALTH SYSTEMS FOR HIV AND/OR COVID-19 IN COTE D'IVOIRE, ETHIOPIA, HAITI, KENYA, NAMIBIA, NIGERIA, RWANDA, VIETNAM, AND ZAMBIA.IN 2021, PATH SUPPORTED THE LAUNCH OF THE DIGITAL HEALTH APPLIED LEADERSHIP PROGRAM, A YEAR-LONG TRAINING THAT ENHANCES PARTICIPANTS' CAPACITY TO SUCCESSFULLY LEAD AND EXECUTE DIGITAL HEALTH PROGRAMS. DESIGNED WITH A COMPREHENSIVE LEADERSHIP CURRICULUM FOR A DIVERSE COHORT OF LEARNERS, THE PROGRAM CONSISTS OF CORE ONLINE COURSES, WORKSHOPS, INSTRUCTION FROM TUTORS, AND GUIDANCE FOR PLANNING AND DELIVERING A PROJECT TO BUILD DIGITAL HEALTH CAPACITY ACROSS PARTICIPATING COUNTRIES.PATH CONTINUED TO PARTICIPATE IN HIGH-LEVEL GLOBAL COALITIONS, INCLUDING TRANSFORM HEALTH, WHICH SUPPORTS THE DEVELOPMENT OF HEALTH DATA GOVERNANCE PRINCIPLES; THE LANCET/FINANCIAL TIMES JOINT COMMISSION, WHICH RELEASED ITS REPORT ON GOVERNING HEALTH FUTURES 2030; AND THE DIGITAL CONNECTED CARE COALITION.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM AIMS TO ADVANCE AND INCREASE ACCESS TO HIGH-QUALITY AND APPROPRIATE DIAGNOSTICS THAT IMPROVE THE HEALTH OUTCOMES OF PEOPLE AND COMMUNITIES IN LOW-RESOURCE SETTINGS.IN 2021, OUR PIONEERING WORK SUPPORTED THE ADVANCEMENT OF AFFORDABLE, RELIABLE DIAGNOSTICS, PROTEINS, ANTIBODIES, AND TOOLS BY AIDING THE DEVELOPMENT, COMMERCIALIZATION, AND PROCUREMENT OF NEW TECHNOLOGIES; SECURING REGULATORY APPROVAL; CONDUCTING PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; AND PUBLISHING 18 PEER-REVIEWED ARTICLES.IN RESPONSE TO THE GLOBAL COVID-19 PANDEMIC, WE SUPPORTED THE DEVELOPMENT AND VALIDATION OF DIAGNOSTIC TOOLS, TECHNOLOGIES, AND SOLUTIONS SUITABLE FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS). THIS INCLUDED DEVELOPING MULTIPLE PUBLICLY AVAILABLE INTERACTIVE COVID-19 DIAGNOSTIC DASHBOARDS TO SUPPORT DATA-DRIVEN PRODUCT SELECTION AND PROCUREMENT DECISIONS; CREATING A COVID-19 SAMPLE REPOSITORY TO SUPPORT DEVELOPERS IN ACCESSING CLINICAL SAMPLES FOR RESEARCH AND DEVELOPMENT; ENSURING THE QUALITY OF COVID-19 RAPID DIAGNOSTIC TESTS WITH A BENCHMARKING PANEL THAT ENABLES UNBIASED, COMPARATIVE EVALUATIONS BETWEEN COVID-19 TESTS; SUPPORTING THE NATIONAL RESPONSE IN BRAZIL, INDONESIA, MALAWI, NEPAL, AND PAKISTAN TO DETECT AND QUANTIFY THE PRESENCE OF SARS-COV-2 IN WASTEWATER; AND CONDUCTING CLINICAL AND OPERATIONAL STUDIES TO ENSURE THAT COVID-19 POINT-OF-CARE TESTS ARE AN EFFECTIVE MEANS OF COMBATTING COVID-19 IN SETTINGS WHERE LABORATORY RESULTS ARE DELAYED OR UNAVAILABLE.IN MAY 2021, THE SD BIOSENSOR STANDARD G6PD TEST RECEIVED REGULATORY APPROVAL FROM THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION (TGA). PATH HELPED GUIDE THE TEST THROUGH PRODUCT DEVELOPMENT AND CLINICAL EVIDENCE GENERATION FOR SUBMISSION TO THE TGA. THIS IS THE FIRST POINT-OF-CARE TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY THAT CAN SUPPORT SAFE ACCESS TO THE CURRENTLY AVAILABLE DRUGS FOR PLASMODIUM VIVAX MALARIA.IN COLLABORATION WITH THE UNIVERSITY OF QUEENSLAND'S PROTEIN EXPRESSION FACILITY, PATH ADVANCED THE COMMERCIALIZATION OF HIGHLY SPECIFIC AND SENSITIVE MALARIA ANTIGEN REAGENTS FOR IMMUNOLOGICAL TESTS. THESE NEWLY AVAILABLE CUSTOM PROTEINS WILL FACILITATE DEVELOPMENT AND PERFORMANCE BENCHMARKING OF RAPID, ACCURATE, SPECIES-SPECIFIC MALARIA DIAGNOSTICS. THE DIAGNOSTICS TEAM CONTINUED TO MANAGE A COMMUNITY OF PRACTICE FOR G6PD OPERATIONAL RESEARCH AND HOSTED SIX INFORMATION-SHARING WEBINARS.IN COLLABORATION WITH THE U.K. NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROLS, PATH WORKED TO DEVELOP AND RELEASE 14 HIGH-QUALITY AND AFFORDABLE MONOCLONAL ANTIBODIES TO SUPPORT DEVELOPMENT OF PNEUMOCOCCAL VACCINES THAT ARE LOW-COST, SEROTYPE-SPECIFIC, AND TAILORED FOR USE BY VACCINE DEVELOPERS AND RESEARCHERS IN LMICS.MEDICAL DEVICES AND HEALTH TECHNOLOGIES THE MEDICAL DEVICES AND HEALTH TECHNOLOGIES PROGRAM IS PATH'S PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE IN LMICS. FOR EXAMPLE, IN COLLABORATION WITH LOCAL STAKEHOLDERS AND RESEARCHERS, WE DEVELOP FIT-FOR-PURPOSE HEALTH TECHNOLOGIES SUCH AS THE ELLAVI UTERINE BALLOON TAMPONADE (UBT), A LIFESAVING INTERVENTION FOR POSTPARTUM HEMORRHAGE. IN 2021, THE ELLAVI UBT'S AVAILABILITY GREW TO 16 COUNTRIES. THE CAYA DIAPHRAGM, ANOTHER PATH-DEVELOPED MEDICAL DEVICE, ACHIEVED REGULATORY APPROVAL IN 7 LATIN AMERICAN COUNTRIES, BRINGING THE GLOBAL TOTAL TO 39 COUNTRIES WHERE THE DEVICE IS NOW AVAILABLE.PATH CONTINUED TO SUPPORT INCLUSIVE INNOVATION, HIRING ADDITIONAL DESIGN AND INNOVATION SPECIALISTS IN AFRICA, WHICH ALLOWED THE LIVING LABS INITIATIVE TO CO-CREATE WITH APPROXIMATELY 1,000 FRONTLINE HEALTH WORKERS AND COMMUNITY MEMBERS. THE PATH MICROARRAY PATCH CENTER OF EXCELLENCE CONTINUED OUR CROSS-SECTOR WORK TO ADVANCE THIS NEEDLE-FREE DELIVERY TECHNOLOGY PLATFORM FOR MEASLES, RUBELLA, AND COVID-19 VACCINES.FINALLY, WE CONVENED A GLOBAL SYRINGE MANUFACTURER WORKSHOP AND PRODUCED AN AUTODISABLE SYRINGE GAP ANALYSIS MODEL TO INFORM GLOBAL STAKEHOLDERS AND U.S. DECISION-MAKERS. WE ALSO PRODUCED AND SHARED GLOBAL COLD CHAIN MODELING DATA FOR COVID-19 VACCINES ACROSS 92 ADVANCED MARKET COMMITMENT COUNTRIES. TO ADDRESS THE URGENT NEED FOR A COVID-19 VACCINE THAT IS THERMOSTABLE AND NEEDLE-FREE, THE FORMULATION TEAM SUBMITTED A PATENT APPLICATION FOR A FREEZE-DRIED FORMULATION OF AN MRNA VACCINE SUITABLE FOR ORAL AND PARENTERAL ADMINISTRATION.MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM WORKS TO INCREASE EQUITABLE ACCESS TO HEALTH PRODUCTS AND SERVICES BY DIAGNOSING THE ROOT CAUSES OF MARKET FAILURES, DESIGNING APPROPRIATE SOLUTIONS, AND DEVELOPING SUSTAINABLE AND INCLUSIVE HEALTH MARKETS. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT/INTRODUCTION AND HEALTH SYSTEMS STRENGTHENING, AND IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, AND PATH'S COUNTRY PROGRAMS. IN 2021, OUR LARGEST AREAS OF WORK WERE:
4b
(Code:
) (Expenses $
100,080,790
including grants of $
33,744,940
) (Revenue $
)
ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LMICS. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE.IN 2021, PATH CONTINUED TO SUPPORT THE GLOBAL COVID-19 RESPONSE BY PROVIDING EXPERTISE TO THE COVAX FACILITY, SUPPORTING VACCINE SUPPLY CHAIN NETWORKS, PROVIDING TECHNICAL ASSISTANCE AND TRAINING TO VACCINE MANUFACTURERS, STRENGTHENING CLINICAL RESEARCH CENTER AND COUNTRY DELIVERY READINESS, AND TRAINING PHARMACISTS AS VACCINATORS IN GHANA. WE ALSO SUPPORTED THE MRNA VACCINE TECHNOLOGY HUB IN SOUTH AFRICA AND PROVIDED COORDINATION AND TECHNICAL ASSISTANCE FOR A CONSORTIUM DEVELOPING AN EGG-BASED COVID-19 VACCINE FOR PRODUCTION IN BRAZIL, THAILAND, VIETNAM, AND OTHER LMICS. ADDITIONALLY, PATH GUEST EDITED A SPECIAL ISSUE OF VACCINE INSIGHTS ON COVID-19.IN ONGOING EFFORTS TO FACILITATE LOCAL VACCINE PRODUCTION, PATH SUPPORTED VIETNAM-BASED MANUFACTURER POLYVAC TO ESTABLISH A SYSTEM FOR CONDUCTING POST-LICENSURE VACCINE SAFETY SURVEILLANCE AND DATA ANALYSIS. THIS NEW SYSTEM ENSURES POLYVAC'S COMPLIANCE WITH LOCAL AND GLOBAL REGULATORY REQUIREMENTS. PATH ALSO SUPPORTED CHINESE VACCINE MANUFACTURERS TO READY LOCALLY MADE VACCINES FOR THE GLOBAL MARKET, THEREBY INCREASING AVAILABLE INTERVENTIONS AND POTENTIALLY MAKING VACCINES MORE ACCESSIBLE FOR LMICS. WE HELPED LAUNCH A PHASE 3 CLINICAL STUDY IN KENYA OF A YELLOW FEVER VACCINE FROM BEIJING INSTITUTE OF BIOLOGICAL PRODUCTS. DATA FROM THE STUDY WILL SUPPORT AN APPLICATION FOR WHO PREQUALIFICATION (PQ), A KEY STEP FOR GLOBAL AVAILABILITY. WE PROVIDED TECHNICAL ASSISTANCE TO SEVERAL OTHER MANUFACTURERS PREPARING FOR WHO PQ SUBMISSION OR INSPECTION; THUS IN 2021, SINOVAC BIOTECH LTD'S COVID-19 VACCINE, CORONAVAC, RECEIVED EMERGENCY USE LISTING, AND XIAMEN INNOVAX BIOTECH'S HPV VACCINE, CECOLIN, RECEIVED WHO PQ. PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. BASED ON THE REAL-WORLD PERFORMANCE OF A NOVEL ORAL POLIO VACCINE AGAINST TYPE 2 POLIOVIRUS (NOPV2), THE WHO STRATEGIC ADVISORY GROUP OF EXPERTS ON IMMUNIZATION (SAGE) ENDORSED WIDER USE OF NOPV2 UNDER THE EMERGENCY USE LISTING. PATH ALSO LAUNCHED A PHASE 3 STUDY OF NOPV2 AND A PHASE 1 STUDY OF NOPV1.THROUGHOUT THE YEAR, PATH AND OUR PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. PATH LAUNCHED A NEW STUDY ON THE COST OF ILLNESS FOR JE AND ITS LONG-TERM CONSEQUENCES IN BANGLADESH, LAOS, AND VIETNAM. WE ALSO WORKED CLOSELY WITH THE GOVERNMENT OF BANGLADESH AND LOCAL PARTNERS TO INFORM THE COUNTRY'S JE VACCINATION DECISION-MAKING, WITH AN APPLICATION TO GAVI, THE VACCINE ALLIANCE (GAVI) EXPECTED IN 2022.ALSO IN 2021, WE CONTINUED A PIVOTAL PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE. THIS VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGOCOCCAL MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE CONTRIBUTED TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL DEFEATING MENINGITIS BY 2030 INITIATIVE AND SUPPORTED THE WHO CELEBRATION AND LAUNCH OF DEFEATING MENINGITIS BY 2030: A GLOBAL ROAD MAP.PATH ACCELERATED THE DEVELOPMENT AND INTRODUCTION OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. WE CONTINUED TO WORK WITH WHO; THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI; AND OTHER PARTNERS TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. IN 2021, THE VACCINE RECEIVED A RECOMMENDATION FROM WHO FOR BROAD USE TO CURB PLASMODIUM FALCIPARUM MALARIA IN CHILDREN LIVING IN MODERATE-TO-HIGH MALARIA TRANSMISSION AREAS. WE CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO STRETCH LIMITED VACCINE SUPPLIES. WE ALSO RESEARCHED USE OF THE VACCINE TO AVERT HIGHLY SEASONAL MALARIA ALONGSIDE SEASONAL MALARIA CHEMOPREVENTION. WE CONTINUED WORK TO IDENTIFY IMMUNE CORRELATES OF PROTECTION AND STUDY THE USE OF MONOCLONAL ANTIBODIES TO PREVENT MALARIA, AND WE CONTINUED WORK ON A FIVE-YEAR CONTRACT FROM USAID TO ADVANCE PRE-ERYTHROCYTIC, BLOOD-STAGE, AND COMBINATION MALARIA VACCINE APPROACHES.THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE, THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN LMICS. A MAJOR FOCUS OF 2021 WAS HIGHLIGHTING CLIMATE CHANGE AND GENDER INEQUITY AS MAJOR DRIVERS OF CHILD HEALTH OUTCOMES.TO REDUCE THE BURDEN OF ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, PATH CONTINUED CLINICAL DEVELOPMENT OF AN INJECTABLE NONREPLICATING ROTAVIRUS VACCINE CANDIDATE WITH THE START OF A PHASE 3 EFFICACY STUDY AT THREE CLINICAL SITES IN AFRICA. PATH ALSO BEGAN A PHASE 2 STUDY WITH THIS CANDIDATE IN SOUTH AFRICA TO EXAMINE IMMUNE RESPONSES TO DIFFERENT COMBINATIONS OF ORAL AND INJECTED ROTAVIRUS VACCINES. IN ADDITION, PATH CONTINUED A CASE-CONTROL STUDY IN INDIA TO EVALUATE THE EFFECTIVENESS OF SERUM INSTITUTE OF INDIA PVT. LTD.'S LICENSED ROTAVIRUS VACCINE, ROTASIIL. PATH CONTINUED TO SUPPORT CLINICAL TRIALS AND RESEARCH ON VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, THE LEADING BACTERIAL CAUSES OF DIARRHEAL ILLNESS. CURRENTLY, THERE ARE NO LICENSED VACCINES AGAINST EITHER PATHOGEN. WE COMPLETED FURTHER ANALYSIS OF RESULTS FROM A PHASE 2B EFFICACY STUDY OF AN ORAL ETEC VACCINE CANDIDATE (ETVAX) IN FINNISH TRAVELERS TO BENIN, WHICH SHOWED ETVAX VACCINATION REDUCED THE NEED FOR ANTIBIOTICS. IN ADDITION, WE COMPLETED IN-DEPTH EXPLORATORY IMMUNOLOGY ANALYSES OF A NOVEL, INJECTABLE SUBUNIT SHIGELLA VACCINE CANDIDATE USING SAMPLES FROM A RECENT PHASE 1 STUDY SUGGESTING EFFECTIVE IMMUNIZATION MAY BE POSSIBLE WITH A SINGLE DOSE.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, A LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE, AND AGAINST PNEUMOCOCCAL DISEASE, A TOP CAUSE OF DEADLY CHILDHOOD PNEUMONIA. WE SUPPORTED INVENTPRISE AS IT WORKS TO DEVELOP MULTIVALENT CONJUGATE VACCINES FOR BOTH DISEASES THAT WILL BE AFFORDABLE FOR LMICS.AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES: IN MALAWI AND NEPAL, WE CONTINUED TO SUPPORT EACH GOVERNMENT IN PLANNING FOR TCV INTRODUCTION; IN PAKISTAN, WE SUPPORTED THE GOVERNMENT IN PLANNING FOR THE CONCLUSION OF THE NATIONAL ROLLOUT; IN LIBERIA AND ZIMBABWE, WE WRAPPED UP OUR SUPPORT AFTER SUCCESSFUL TCV INTRODUCTION CAMPAIGNS; AND IN ADDITIONAL COUNTRIES, WE INITIATED DISCUSSIONS TO SUPPORT DECISION-MAKING. WE CONTINUED TO SHARE NEW DATA AND SERVE AS A HUB FOR TYPHOID INFORMATION, RAISING AWARENESS ON TYPHOID DISEASE AND PREVENTION THROUGH AN INTEGRATED APPROACH THAT INCLUDES VACCINES. TO PREVENT CERVICAL CANCER, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE, ANALYZE, AND DISSEMINATE EVIDENCE ON SINGLE-DOSE HPV VACCINATION. THIS INCLUDED SYNTHESIZING NEWLY AVAILABLE, CRITICAL CLINICAL TRIAL DATA TO PREPARE FOR AND PRESENT EVIDENCE TO WHO'S SAGE. A SINGLE-DOSE SCHEDULE WOULD HELP ALLEVIATE COUNTRIES' FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO HPV VACCINE INTRODUCTION. PATH ALSO SPONSORED A PHASE 3 STUDY OF A LICENSED HPV VACCINE IN GHANA AND BANGLADESH TO GENERATE EVIDENCE IN LMICS AND ON EXTENDED DOSING SCHEDULES, AND CONTINUED DATA COLLECTION FOR AN HPV COST-OF-DELIVERY STUDY IN SIX COUNTRIES WITH HPV VACCINATION PROGRAMS.
4c
(Code:
) (Expenses $
37,745,269
including grants of $
4,420,524
) (Revenue $
)
AFRICA REGION: PATH'S WORK IN AFRICA INTERSECTS VIRTUALLY EVERY PATH GLOBAL PROGRAM, FROM ADVOCACY AND PUBLIC POLICY TO SEXUAL AND REPRODUCTIVE HEALTH. WE HAVE COUNTRY OFFICES IN SEVEN SUB-SAHARAN NATIONS SPANNING CENTRAL, EASTERN, SOUTHERN, AND WESTERN AFRICA: THE DRC, ETHIOPIA, KENYA, SENEGAL, TANZANIA, UGANDA, AND ZAMBIA - WITH PROJECT OFFICES IN SEVEN MORE. HIGHLIGHTS FROM OUR COUNTRY OFFICES INCLUDE:(CONTINUED ON SCHEDULE O)DRCIN 2021, PATH'S ENGAGEMENT IN THE DRC FOCUSED ON HIV/AIDS, VACCINATION (COVID-19 AND POLIO), AND HEALTH SYSTEM STRENGTHENING. FOR EXAMPLE, THE USAID INTEGRATED HIV/AIDS PROJECT, WHICH PATH LEADS IN HAUT-KATANGA PROVINCE (IHAP-HK), ACHIEVED THE INTERNATIONAL GOLD STANDARD RATE OF 95% UNDETECTABLE VIRAL LOAD AMONG A COHORT OF 45,000. PATH ALSO SUPPORTED THE COVID-19 RESPONSE, INCLUDING HOSTING THE PRESIDENTIAL COVID-19 TASK FORCE IN OUR KINSHASA OFFICE, CONDUCTING THE FIRST DRC NATIONWIDE OXYGEN AVAILABILITY ASSESSMENT, AND MONITORING COVID-19 VACCINATION (THE LATTER VIA THE USAID M-RITE PROJECT). PATH SUPPORTED THE DRC PRESIDENT'S OFFICE FOR THE SECOND PRESIDENTIAL IMMUNIZATION AND POLIO ERADICATION FORUM. TO ACCELERATE TWO HIGH-PRIORITY INITIATIVES - THE DIGITAL TRANSFORMATION OF THE COUNTRY'S HEALTH SECTOR AND UNIVERSAL HEALTH COVERAGE - THE MOH, WITH SUPPORT FROM THE DIGITAL SQUARE TEAM WITHIN PATH, LAUNCHED AN INVESTMENT ROAD MAP WITH MORE THAN 60 INSTITUTIONS PARTICIPATING IN PRIORITIZING CATALYTIC INVESTMENTS.ETHIOPIAWITH FUNDING FROM GAVI THROUGH THE TARGETED COUNTRY ASSISTANCE (TCA) PROJECT, PATH SUPPORTED THE AFAR REGION TO PILOT AND IMPLEMENT CATCH-UP IMMUNIZATION IN TWO CONFLICT-AFFECTED AREAS. PATH ALSO SUPPORTED THE MOH TO IMPLEMENT A VACCINATION STRATEGY DESIGNED SPECIFICALLY FOR COVID-19 VACCINE AND HPV VACCINE, CONDUCTING AN INTEGRATED VACCINATION CAMPAIGN NATIONWIDE FOR TWO COHORTS OF ADOLESCENT GIRLS AND YOUNG WOMEN. IN CLOSE COLLABORATION WITH THE MOH, PATH DESIGNED AND WAS AWARDED A PROJECT FROM BIG WIN PHILANTHROPY TO REVAMP AND RESTORE MATERNAL AND CHILD HEALTH PROGRAMS IN CONFLICT-AFFECTED AREAS, WITH A FOCUS ON EARLY CHILDHOOD DEVELOPMENT AND CAREGIVER HEALTH.KENYAPATH'S NONCOMMUNICABLE DISEASES (NCD) TEAM PARTNERED WITH THE KENYA GOVERNMENT TO EVALUATE THE NATIONAL NCD STRATEGY 2015-2020 TO INFORM THE DESIGN AND DEVELOPMENT OF THE NCD STRATEGY 2021-2026. FOLLOWING LAUNCH OF THE STRATEGY IN JULY 2021, PATH SUPPORTED DISSEMINATION TO OUR FOCAL COUNTIES. PATH IS PRIME ON THE PEPFAR-FUNDED USAID NURU YA MTOTO PROJECT, WITH A FIVE-YEAR (2021-2026) BUDGET OF MORE THAN $44 MILLION. THROUGH THIS PROJECT, PATH LEADS A CONSORTIUM THAT PROVIDES HIV SERVICES TO YOUNG PEOPLE IN HOMA BAY, KISII, AND MIGORI COUNTIES. THROUGH THE DREAMS INITIATIVE, WE CONTINUED TO SUPPORT HIV PREVENTION FOR ADOLESCENT GIRLS AND YOUNG WOMEN. WORKING AS A SUBPARTNER, PATH ALSO SUPPORTED BORESHA JAMII, A PEPFAR-FUNDED USAID PROJECT TO INCREASE ACCESS TO AND DEMAND FOR HIGH-QUALITY TB/HIV PREVENTION, CARE, AND TREATMENT.RTS,S, THE WORLD'S FIRST MALARIA VACCINE, WAS DEVELOPED BY GSK OVER MORE THAN 30 YEARS AND IN PARTNERSHIP WITH PATH SINCE 2001. IN OCTOBER 2021, WHO RECOMMENDED EXPANDING USE OF THE VACCINE ACROSS THE AFRICAN CONTINENT. WITH PATH SUPPORT, KENYA, ONE OF THE FIRST COUNTRIES TO GAIN REGULATORY APPROVAL FOR RTS,S, EMBARKED ON A PHASED INTRODUCTION AND EVALUATION TO LEARN HOW BEST TO IMPLEMENT THE VACCINE WITHIN THE CONTEXT OF ROUTINE IMMUNIZATION.THE PATH KENYA LIVING LABS TEAM IN 2021 FINALIZED THE DESIGN AND PILOT TESTING OF A PROTOTYPE DIGITAL TOOL TO SUPPORT SCHEDULING FOR BOTH IMMUNIZATION AND PHC SERVICES. THE TOOL COMPLEMENTS AN IMMUNIZATION DASHBOARD DEVELOPED BY THE LIVING LABS TEAM TO TRACK PERFORMANCE ON KEY INDICATORS ACROSS KENYA'S COUNTIES, SUBCOUNTIES, AND FACILITIES. KENYA IS ONE OF SEVERAL COUNTRIES RECEIVING SUPPORT THROUGH THE COVID-19 RESPIRATORY CARE RESPONSE COORDINATION PROJECT, A CONSORTIUM FUNDED BY THE BILL & MELINDA GATES FOUNDATION. IN 2021, THE CONSORTIUM, LED BY PATH, PROCURED AND INSTALLED RESPIRATORY CARE EQUIPMENT AT 23 HIGH-VOLUME FACILITIES AND ENSURED THE REPAIR/INSTALLATION OF FIVE OXYGEN GENERATION PLANTS AT TERTIARY/REFERRAL HEALTH FACILITIES. ADDITIONALLY, PATH SUPPORTED KENYAN COUNTIES IN CONDUCTING CAPACITY-BUILDING AND SUPPORTIVE SUPERVISION UNDER THE M-RITE PROJECT, WHICH FOCUSES ON IMMUNIZATION.SENEGALPATH PROVIDED TECHNICAL ASSISTANCE AND LOGISTICAL SUPPORT TO THE MOH IN ROLLING OUT THE 3RD EDITION OF THE INTEGRATED DISEASE SURVEILLANCE AND RESPONSE SYSTEM, A KEY TOOL IN IDENTIFYING, MANAGING, AND MITIGATING INFECTIOUS DISEASE OUTBREAKS. RELATED, PATH PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF LABORATORIES AND THE MOH IN DEVELOPING AND VALIDATING NATIONAL STANDARD OPERATING PROCEDURES FOR DETECTION AND SURVEILLANCE OF ANTIMICROBIAL RESISTANCE (AMR).PATH SUPPORTED THE GOVERNMENT IN VARIOUS ASPECTS OF ITS COVID-19 RESPONSE, INCLUDING PROCUREMENT OF EQUIPMENT AND REAGENTS FOR DIAGNOSTIC TESTS AS WELL AS INTENSIVE CARE EQUIPMENT FOR TREATMENT OF SEVERE CASES. AT THE COMMUNITY LEVEL, PATH WORKED TO STIMULATE DEMAND FOR COVID-19 VACCINATION.IN 2021, THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (TIMCI) PROJECT LAUNCHED IN SENEGAL, AND THE TRAINING, SUPERVISION, AND COMMUNITY ENGAGEMENT PHASE BEGAN WITH IMPLEMENTATION AT FOUR INTERVENTION SITES. TIMCI (WITH PATH AS LEAD PARTNER) SUPPORTED THE MOH TO REVISE THE COUNTRY'S INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS GUIDELINES WITH THE SPECIFIC OBJECTIVE OF INCLUDING PULSE OXIMETRY AND OXYGEN THERAPY INDICATIONS. AS PATH'S WESTERN AFRICA HUB, PATH SENEGAL SUPPORTED THE MOH OF GUINEA, A NEIGHBORING COUNTRY, IN INTEGRATING ALL VIRAL HEMORRHAGIC FEVERS, INCLUDING EBOLA, INTO ITS NATIONAL SURVEILLANCE EARLY WARNING SYSTEM. PATH ALSO PROVIDED TECHNICAL ASSISTANCE TO THE GOVERNMENT OF MALI IN THE DIGITALIZATION OF COVID-19 VACCINATION DATA.TANZANIAIN 2021, THE DATA USE PARTNERSHIP, A COLLABORATION BETWEEN PATH AND THE GOVERNMENT OF TANZANIA, LAUNCHED THE AFYA SUPPORTIVE SUPERVISION PLAN TO IMPLEMENT A DIGITAL SYSTEM FOR DATA COLLECTION IN HEALTH FACILITIES. THE PLAN SUPPLIED 900 TABLETS TO NATIONAL- AND REGIONAL-LEVEL USERS, WITH PATH LEVERAGING OUR EXPERTISE TO SUPPORT TRAININGS ON THE EQUIPMENT AND SOFTWARE.ALSO IN TANZANIA, THE INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT OPERATIONALIZED A NATIONAL AMR SURVEILLANCE FRAMEWORK. HEALTH WORKERS IN THE COUNTRY CAN NOW SUBMIT HIGH-QUALITY AMR DATA PRODUCED THROUGH THIS FRAMEWORK TO THE NATIONAL DATABASE AND THE GLOBAL AMR SURVEILLANCE SYSTEM.IN COLLABORATION WITH THE MOH, PATH LAUNCHED THE TIMCI PROJECT IN THREE DISTRICTS. WORK IN 2021 INCLUDED DEVELOPING, DEPLOYING, AND SUPPORTING IMPLEMENTATION OF AN ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHM. PATH'S DIGITAL SQUARE INITIATIVE SUPPORTED THE MOH IN IMPLEMENTING A STANDARDS-BASED NATIONAL HEALTH INFORMATION EXCHANGE PLATFORM THAT BY CLOSE OF 2021 ALLOWED FOR EXCHANGE OF DATA BETWEEN 13 DISPARATE HEALTH INFORMATION SYSTEMS. THROUGH GAVI/TCA, PATH SUPPORTED THE MOH TO TRANSITION FROM A TRADITIONAL, PAPER-BASED SYSTEM FOR IMMUNIZATION TRACKING TO FULL ELECTRONIC DATA COLLECTION AND MANAGEMENT IN MORE THAN 600 PHC FACILITIES. SEPARATELY, PATH SUPPORTED THE MOH TO DEVELOP A RESPIRATORY CARE EQUIPMENT BASELINE ASSESSMENT TOOL, MEDICAL OXYGEN TRAINING MANUAL, AND SCALE-UP PLAN.IN LATE 2021, THE HEALTHY HEART AFRICA PROJECT BEGAN IN TANZANIA WITH THE SIGNING OF A MEMORANDUM OF UNDERSTANDING BETWEEN THE MOH AND ASTRAZENECA, AFTER WHICH PATH CONDUCTED A STAKEHOLDER WORKSHOP TO INTRODUCE THE PROJECT AND ENSURE GOVERNMENT COMMITMENT AND ACCOUNTABILITY. UGANDAIN 2021, PATH'S ADVOCACY AND PUBLIC POLICY TEAM IN UGANDA INFLUENCED THE INTRODUCTION OF A SUPPLEMENTARY BUDGET FOR COVID-19 VACCINATION AND ENSURED BUDGET INCREASES FROM PREVIOUS YEARS FOR ROUTINE IMMUNIZATION AND PHC WERE MAINTAINED DESPITE BUDGET SHORTFALLS AT THE NATIONAL LEVEL. PATH SUCCESSFULLY ADVOCATED FOR THE PASSAGE OF A NATIONAL HEALTH INSURANCE SCHEME AND HELPED DEVELOP A UNIVERSAL HEALTH COVERAGE ROAD MAP AND COMMUNITY HEALTH EXTENSION WORKERS STRATEGY IN PILOT DISTRICTS. OUR TEAM ADVOCATED FOR INTEGRATION OF THE ADDIS DECLARATION ON IMMUNIZATION COMMITMENTS INTO EXPANDED PROGRAM ON IMMUNIZATION WORK PLANS BY CREATING AND DISSEMINATING A SCORECARD TOOL TO SERVE AS AN ACCOUNTABILITY FRAMEWORK. PATH IN UGANDA ALSO ADVOCATED FOR PRIORITIZATION OF ROUTINE IMMUNIZATION TO PREVENT BACKSLIDING DURING COVID-19, WITH A FOCUS ON CATCH-UP CAMPAIGNS SUCH AS A NATIONAL POLIO IMMUNIZATION CAMPAIGN. PATH ALSO SUPPORTED THE MOH TO DISSEMINATE GUIDELINES ON THE CONTINUITY OF ESSENTIAL HEALTH SERVICES DURING COVID-19 AT THE SUBNATIONAL LEVEL, REACHING MORE THAN 400 CHAMPIONS AND HEALTH CARE WORKERS THROUGH TECHNICAL WORKSHOPS AND TRAININGS.
(Code:
) (Expenses $
41,899,328
including grants of $
5,057,232
) (Revenue $
)
ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, IN AFRICA (DRC, KENYA, SOUTH AFRICA, AND UGANDA), AND AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES. WE PARTNER WITH POLICYMAKERS TO HELP THEM UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. AS A 501(3)C ORGANIZATION, PATH DOES NOT INFLUENCE THE OUTCOMES OF ELECTIONS AND DOES NOT EMPLOY ANY REGISTERED LOBBYISTS. PATH PROVIDES BEHIND-THE-SCENES SUPPORT TO ADVOCACY PARTNERS IN THE PLACES WHERE WE WORK TO HELP STRENGTHEN THEIR CAPACITY TO ENGAGE WITH LOCAL DECISION-MAKERS TO IMPROVE HEALTH IN THEIR COMMUNITIES. WE FACILITATE PEER-TO-PEER LEARNINGS AMONG THESE PARTNERS TO EXCHANGE BEST PRACTICES AND LESSONS LEARNED ABOUT THE PRACTICE OF ADVOCACY, AND WE HELP ELEVATE LOCAL VOICES IN GLOBAL CONVERSATIONS AROUND HEALTH. IN 2021, PATH LED EFFORTS TO ENSURE SUPPORT AMONG OUR PARTNER POLICYMAKERS TO MAINTAIN AND STRENGTHEN PIVOTAL WORK IN GLOBAL HEALTH RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, PHC, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY U.S. GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS AND HELPING DECISION-MAKERS SHAPE THE GLOBAL RESPONSE TO COVID-19.ASIA, MIDDLE EAST, AND EUROPE REGIONPATH'S LEADERSHIP IN THE ASIA, MIDDLE EAST, AND EUROPE (AMEE) REGION LEVERAGES OUR DEEP EXPERTISE ACROSS MULTIPLE HEALTH DISCIPLINES TO CHAMPION EQUITY IN ACCESS TO CARE, INTRODUCE NEW TECHNOLOGIES AND APPROACHES, AND PARTNER ACROSS SECTORS TO PROVIDE HUMAN-CENTERED CARE AND SUPPORT. PATH COORDINATES OUR WORK IN THIS REGION FROM OFFICES IN EIGHT COUNTRIES, INCLUDING OFFICES IN CHINA, INDIA, UKRAINE, AND VIETNAM THAT SERVE AS REGIONAL HUBS FOR TECHNICAL AND SCIENTIFIC INNOVATION. HIGHLIGHTS INCLUDE:IN 2021, PATH CONTINUED TO COLLABORATE CLOSELY WITH STAKEHOLDERS TO DELIVER HIGH-QUALITY HEALTH SERVICES WHILE FORGING NEW PARTNERSHIPS IN COUNTRIES SUCH AS BANGLADESH, INDONESIA, LAOS, AND NEPAL AND EXPLORING COLLABORATIONS IN NEW GEOGRAPHIES IN THE MIDDLE EAST.PATH PREPARED AND RESPONDED TO EMERGING HEALTH THREATS IN THE REGION BY PROVIDING TECHNICAL SUPPORT, ENHANCING LABORATORY CAPACITY, STRENGTHENING RESPIRATORY CARE RESPONSE, IMPROVING THE COVID-19 SURVEILLANCE SYSTEM, AND LEVERAGING OUR NETWORK OF PARTNERS TO SUPPORT PANDEMIC RESPONSE. IN ADDITION TO THE COVID-19 EMERGENCY, WE COMMITTED TO ELIMINATE LONG-NEGLECTED DISEASES SUCH AS LEISHMANIASIS AND ENSURE THAT THOSE INFECTED RECEIVE CARE.THANKS TO OUR CONTINUOUS WORK IN DEVELOPING INNOVATIVE DIGITAL HEALTH TOOLS, PATH WAS ABLE TO MAINTAIN ESSENTIAL HEALTH SERVICES FOR KEY POPULATIONS IN MYANMAR, DIGITIZE THE LACTATION MANAGEMENT SYSTEM IN INDIA, AND SUPPORT MEDICATION ADHERENCE FOR TB PATIENTS IN UKRAINE. THROUGHOUT THE YEAR, AMEE PROGRAMS FOCUSED ON INCREASING HEALTH SYSTEM CAPACITY AND RESILIENCE WITH COMMUNITY-BASED APPROACHES THAT BRING AWARENESS, AVAILABILITY, AND ACCESSIBILITY OF HEALTH SERVICES TO HARD-TO-REACH COMMUNITIES. IN VIETNAM, FOR EXAMPLE, WE IMPLEMENTED A HIGHLY SUCCESSFUL PROGRAM FOR HIV SELF-TESTING. PATH IN THE AMEE REGION ALSO CONTINUED OUR CLOSE COLLABORATION WITH WHO, UNICEF, GAVI, AND THE GLOBAL FUND ON LARGE-SCALE EFFORTS TO CONTROL AND ELIMINATE DEBILITATING DISEASES SUCH AS MALARIA AND MENINGITIS; TO IMPROVE ACCESS TO LIFESAVING VACCINES FOR CERVICAL CANCER, DIARRHEAL DISEASE, AND PNEUMOCOCCAL DISEASE IN LOW-INCOME COUNTRIES; AND TO STRENGTHEN VACCINE MANUFACTURING CAPACITY AND THE COLD CHAIN AS PART OF OUR ONGOING EFFORTS TO BRING HEALTH AND WELL-BEING TO ALL.
4d
Other program services (Describe in Schedule O.)
(Expenses $
41,899,328
including grants of $
5,057,232
) (Revenue $
)
4e
Total program service expenses
301,134,100
Form
990
(2021)
Form 990 (2021)
Page
3
Part IV
Checklist of Required Schedules
Yes
No
1
Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)?
If "Yes," complete Schedule A
.....................
1
Yes
2
Is the organization required to complete
Schedule B, Schedule of Contributors
? See instructions.
...
2
Yes
3
Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office?
If "Yes," complete Schedule C,
Part I
.............
3
No
4
Section 501(c)(3) organizations.
Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year?
If "Yes," complete Schedule C,
Part II
.........
4
Yes
5
Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Rev. Proc. 98-19?
If "Yes," complete Schedule C,
Part III
..
5
No
6
Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts?
If "Yes," complete
Schedule D,
Part I
.........................
6
No
7
Did the organization receive or hold a conservation easement, including easements to preserve open space,
the environment, historic land areas, or historic structures?
If "Yes," complete Schedule D,
Part II
....
7
No
8
Did the organization maintain collections of works of art, historical treasures, or other similar assets?
If "Yes,"
complete Schedule D,
Part III
..............
8
No
9
Did the organization report an amount in
Part X
, line 21 for escrow or custodial account liability; serve as a custodian for amounts not listed in
Part X
; or provide credit counseling, debt management, credit repair, or debt negotiation services?
If "Yes," complete Schedule D,
Part IV
..............
9
No
10
Did the organization, directly or through a related organization, hold assets in temporarily restricted endowments, permanent endowments, or quasi endowments?
If "Yes," complete Schedule D,
Part V
......
10
Yes
11
If the organization’s answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X, as applicable.
a
Did the organization report an amount for land, buildings, and equipment in
Part X
, line 10?
If "Yes," complete
Schedule D,
Part VI
.
...................
11a
Yes
b
Did the organization report an amount for investments—other securities in
Part X
, line 12 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VII
.......
11b
No
c
Did the organization report an amount for investments—program related in
Part X
, line 13 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VIII
.......
11c
No
d
Did the organization report an amount for other assets in
Part X
, line 15 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part IX
............
11d
No
e
Did the organization report an amount for other liabilities in
Part X
, line 25?
If "Yes," complete Schedule D,
Part X
11e
No
f
Did the organization’s separate or consolidated financial statements for the tax year include a footnote that addresses the organization’s liability for uncertain tax positions under FIN 48 (ASC 740)?
If "Yes," complete Schedule D,
Part X
11f
No
12a
Did the organization obtain separate, independent audited financial statements for the tax year?
If "Yes," complete
Schedule D, Parts XI and XII
......................
12a
No
b
Was the organization included in consolidated, independent audited financial statements for the tax year?
If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional
12b
Yes
13
Is the organization a school described in section 170(b)(1)(A)(ii)?
If "Yes," complete Schedule E
13
No
14a
Did the organization maintain an office, employees, or agents outside of the United States?
.....
14a
Yes
b
Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more?
If "Yes," complete Schedule F, Parts I and IV
.........
14b
Yes
15
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization?
If “Yes,” complete Schedule F, Parts II and IV
.....
15
Yes
16
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals?
If “Yes,” complete Schedule F, Parts III and IV
...
16
No
17
Did the organization report a total of more than $15,000 of expenses for professional fundraising services on
Part IX
, column (A), lines 6 and 11e?
If "Yes," complete Schedule G,
Part I.
See instructions.
....
17
No
18
Did the organization report more than $15,000 total of fundraising event gross income and contributions on
Part VIII
, lines 1c and 8a?
If "Yes," complete Schedule G,
Part II
............
18
No
19
Did the organization report more than $15,000 of gross income from gaming activities on
Part VIII
, line 9a?
If "Yes," complete Schedule G,
Part III
...................
19
No
20a
Did the organization operate one or more hospital facilities?
If "Yes," complete Schedule H
....
20a
No
b
If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?
20b
21
Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on
Part IX
, column (A), line 1?
If “Yes,” complete Schedule I, Parts I and II
.....
21
Yes
Form
990
(2021)
Form 990 (2021)
Page
4
Part IV
Checklist of Required Schedules
(continued)
Yes
No
22
Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on
Part IX
, column (A), line 2?
If “Yes,” complete Schedule I, Parts I and III
........
22
No
23
Did the organization answer "Yes" to
Part VII
, Section A, line 3, 4, or 5, about compensation of the organization’s current and former officers, directors, trustees, key employees, and highest compensated employees?
If "Yes," complete Schedule J
.......................
23
Yes
24a
Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002?
If “Yes,” answer lines 24b through 24d and complete Schedule K. If “No,” go to line 25a
...............
24a
No
b
Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?
...
24b
c
Did the organization maintain an escrow account other than a refunding escrow at any time during the year
to defease any tax-exempt bonds?
...............
24c
d
Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?
...
24d
25a
Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations.
Did the organization engage in an excess benefit transaction with a disqualified person during the year?
If "Yes," complete Schedule L,
Part I
....
25a
No
b
Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization’s prior Forms 990 or 990-EZ?
If "Yes," complete Schedule L,
Part I
.......................
25b
No
26
Did the organization report any amount on Part X, line 5 or 22 for receivables from or payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons?
If "Yes," complete Schedule L,
Part II
...........
26
No
27
Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or employee thereof, a grant selection committee member, or to a 35% controlled entity (including an employee thereof) or family member of any of these persons?
If "Yes," complete
Schedule L,
Part III
.........................
27
No
28
Was the organization a party to a business transaction with one of the following parties (see the Schedule L,
Part IV
instructions for applicable filing thresholds, conditions, and exceptions):
a
A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor?
If "Yes," complete Schedule L,
Part IV
......................
28a
No
b
A family member of any individual described in line 28a?
If "Yes," complete Schedule L,
Part IV
.....
28b
No
c
A 35% controlled entity of one or more individuals and/or organizations described in line 28a or 28b?
If "Yes," complete Schedule L,
Part IV
.....................
28c
No
29
Did the organization receive more than $25,000 in non-cash contributions?
If "Yes," complete Schedule M
..
29
Yes
30
Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions?
If "Yes," complete Schedule M
.................
30
No
31
Did the organization liquidate, terminate, or dissolve and cease operations?
If "Yes," complete Schedule N,
Part I
31
No
32
Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets?
If "Yes," complete Schedule N,
Part II
........................
32
No
33
Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3?
If "Yes," complete Schedule R,
Part I
............
33
No
34
Was the organization related to any tax-exempt or taxable entity?
If "Yes," complete Schedule R,
Part II
, III, or IV, and
Part V
, line 1
.........................
34
Yes
35a
Did the organization have a controlled entity within the meaning of section 512(b)(13)?
35a
Yes
b
If ‘Yes’ to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)?
If "Yes," complete Schedule R,
Part V
, line 2
...
35b
Yes
36
Section 501(c)(3) organizations.
Did the organization make any transfers to an exempt non-charitable related organization?
If "Yes," complete Schedule R,
Part V
, line 2
.............
36
No
37
Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes?
If "Yes," complete Schedule R,
Part VI
37
No
38
Did the organization complete Schedule O and provide explanations on Schedule O for
Part VI
, lines 11b and 19?
Note.
All Form 990 filers are required to complete Schedule O.
............
38
Yes
Part V
Statements Regarding Other IRS Filings and Tax Compliance
Check if Schedule O contains a response or note to any line in this
Part V
...........
Yes
No
1a
Enter the number reported in box 3 of Form 1096. Enter -0- if not applicable
..
1a
219
b
Enter the number of Forms W-2G included on line 1a. Enter -0- if not applicable
.
1b
0
c
Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?
..................
1c
Yes
Form
990
(2021)
Form 990 (2021)
Page
5
Part V
Statements Regarding Other IRS Filings and Tax Compliance
(continued)
2a
Enter the number of employees reported on Form W-3, Transmittal of Wage and
Tax Statements, filed for the calendar year ending with or within the year covered by this return
..................
2a
667
b
If at least one is reported on line 2a, did the organization file all required federal employment tax returns?
Note.
If the sum of lines 1a and 2a is greater than 250, you may be required to e-file. See instructions.
2b
Yes
3a
Did the organization have unrelated business gross income of $1,000 or more during the year?
...
3a
No
b
If “Yes,” has it filed a Form 990-T for this year?
If “No” to line 3b, provide an explanation in Schedule O
...
3b
4a
At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?
..
4a
Yes
b
If "Yes," enter the name of the foreign country:
BE
,
CH
,
ET
,
GH
,
IN
,
KE
,
MZ
,
PE
,
SG
,
SZ
,
TZ
,
UG
,
UK
,
VM
,
ZA
,
CG
,
MI
,
BM
,
SF
,
UP
See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).
5a
Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?
..
5a
No
b
Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?
5b
No
c
If "Yes," to line 5a or 5b, did the organization file Form 8886-T?
............
5c
6a
Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?
...
6a
No
b
If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?
......................
6b
7
Organizations that may receive deductible contributions under section 170(c).
a
Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?
....................
7a
No
b
If "Yes," did the organization notify the donor of the value of the goods or services provided?
.....
7b
c
Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?
.........................
7c
No
d
If "Yes," indicate the number of Forms 8282 filed during the year
....
7d
e
Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?
7e
No
f
Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?
..
7f
No
g
If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?
......................
7g
h
If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?
..........................
7h
8
Sponsoring organizations maintaining donor advised funds.
Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?
........
8
9
Sponsoring organizations maintaining donor advised funds.
a
Did the sponsoring organization make any taxable distributions under section 4966?
........
9a
b
Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?
...
9b
10
Section 501(c)(7) organizations.
Enter:
a
Initiation fees and capital contributions included on
Part VIII
, line 12
...
10a
b
Gross receipts, included on Form 990,
Part VIII
, line 12, for public use of club facilities
10b
11
Section 501(c)(12) organizations.
Enter:
a
Gross income from members or shareholders
.........
11a
b
Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.)
..........
11b
12a
Section 4947(a)(1) non-exempt charitable trusts.
Is the organization filing Form 990 in lieu of Form 1041?
12a
b
If "Yes," enter the amount of tax-exempt interest received or accrued during the year.
12b
13
Section 501(c)(29) qualified nonprofit health insurance issuers.
a
Is the organization licensed to issue qualified health plans in more than one state?
.........
Note.
See the instructions for additional information the organization must report on Schedule O.
13a
b
Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans
....
13b
c
Enter the amount of reserves on hand
............
13c
14a
Did the organization receive any payments for indoor tanning services during the tax year?
.....
14a
No
b
If "Yes," has it filed a Form 720 to report these payments?
If "No," provide an explanation in Schedule O
..
14b
15
Is the organization subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year?
....................
If "Yes," see the instructions and file Form 4720, Schedule N.
15
No
16
Is the organization an educational institution subject to the section 4968 excise tax on net investment income?
..
If "Yes," complete Form 4720, Schedule O.
16
No
17
Section 501(c)(21) organizations.
Did the trust, any disqualified person, or mine operator engage in any activities that would result in the imposition of an excise tax under section 4951, 4952, or 4953?
..
If "Yes," complete Form 6069.
17
Form
990
(2021)
Form 990 (2021)
Page
6
Part VI
Governance, Management, and Disclosure.
For each "Yes" response to lines 2 through 7b below, and for a "No" response to lines
8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.
Check if Schedule O contains a response or note to any line in this
Part VI
..............
Section A. Governing Body and Management
Yes
No
1a
Enter the number of voting members of the governing body at the end of the tax year
1a
16
If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.
b
Enter the number of voting members included in line 1a, above, who are independent
1b
16
2
Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?
.................
2
No
3
Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person?
.
3
No
4
Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?
.
4
No
5
Did the organization become aware during the year of a significant diversion of the organization’s assets?
.
5
No
6
Did the organization have members or stockholders?
................
6
No
7a
Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?
....................
7a
No
b
Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?
...................
7b
No
8
Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:
a
The governing body?
.......................
8a
Yes
b
Each committee with authority to act on behalf of the governing body?
............
8b
Yes
9
Is there any officer, director, trustee, or key employee listed in
Part VII
, Section A, who cannot be reached at the organization’s mailing address?
If "Yes," provide the names and addresses in Schedule O
.......
9
No
Section B. Policies
(
This Section B requests information about policies not required by the Internal Revenue Code.
)
Yes
No
10a
Did the organization have local chapters, branches, or affiliates?
............
10a
No
b
If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?
10b
11a
Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?
............................
11a
Yes
b
Describe on Schedule O the process, if any, used by the organization to review this Form 990.
.....
12a
Did the organization have a written conflict of interest policy?
If "No," go to line 13
.......
12a
Yes
b
Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?
..........................
12b
Yes
c
Did the organization regularly and consistently monitor and enforce compliance with the policy?
If "Yes," describe on Schedule O how this was done
...................
12c
Yes
13
Did the organization have a written whistleblower policy?
...............
13
Yes
14
Did the organization have a written document retention and destruction policy?
.........
14
Yes
15
Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?
a
The organization’s CEO, Executive Director, or top management official
...........
15a
Yes
b
Other officers or key employees of the organization
................
15b
Yes
If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.
16a
Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?
......................
16a
No
b
If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization’s exempt status with respect to such arrangements?
............
16b
Section C. Disclosure
17
List the states with which a copy of this Form 990 is required to be filed
AL
,
AR
,
CA
,
CT
,
FL
,
IL
,
KS
,
KY
,
MA
,
MD
,
MI
,
MN
,
MS
,
NC
,
NH
,
NJ
,
NM
,
NY
,
OK
,
OR
,
PA
,
RI
,
SC
,
TN
,
UT
,
VA
,
WI
,
WV
18
Section 6104 requires an organization to make its Form 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
Own website
Another's website
Upon request
Other (explain in Schedule O)
19
Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20
State the name, address, and telephone number of the person who possesses the organization's books and records:
KELLY PRIESTLEY CONTROLLER & PRINCIPAL FINANCIAL OFFICER
2201 WESTLAKE AVE SUITE 200
SEATTLE
,
WA
98121
(206) 285-3500
Form
990
(2021)
Form 990 (2021)
Page
7
Part VII
Compensation of Officers, Directors,Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors
Check if Schedule O contains a response or note to any line in this
Part VII
..............
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
1a
Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization’s tax year.
List all of the organization’s
current
officers, directors, trustees (whether individuals or organizations), regardless of amount
of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
List all of the organization’s
current
key employees, if any. See the instructions for definition of "key employee."
List the organization’s five
current
highest compensated employees (other than an officer, director, trustee or key employee)
who received reportable compensation (box 5 of Form W-2, Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than $100,000 from the
organization and any related organizations.
List all of the organization’s
former
officers, key employees, or highest compensated employees who received more than $100,000
of reportable compensation from the organization and any related organizations.
List all of the organization’s
former directors or trustees
that received, in the capacity as a former director or trustee of the
organization, more than $10,000 of reportable compensation from the organization and any related organizations.
See the instructions for the order in which to list the persons above.
Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(F)
Estimated amount of other compensation from the organization and related organizations
(1)
BETH GALETTI MBA
......................................................................
CHAIR
2.00
.................
0.00
X
X
0
0
0
(2)
DAVID KING JD
......................................................................
VICE CHAIR
2.00
.................
0.00
X
X
0
0
0
(3)
SANFORD MELZER
......................................................................
SECRETARY
2.00
.................
0.00
X
X
0
0
0
(4)
BRUCE MCNAMER JD MBA
......................................................................
TREASURER
2.00
.................
0.00
X
X
0
0
0
(5)
YEHONG ZHANG PHD MBA
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(6)
JO ADDY MBA MPA
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(7)
IREENA VITTAL
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(8)
DEANNA OPPENHEIMER
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(9)
JOHN-ARNE ROTTINGEN MD PHD
......................................................................
MSC, MPA--DIRECTOR
2.00
.................
0.00
X
0
0
0
(10)
JOEL HOLSINGER
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(11)
HELENA WAYTH MSC
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(12)
ABAYOMI SULE MBBS MBA
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(13)
LISA ANDERSON
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(14)
RACHEL SIBANDE MSC
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(15)
FREDERICK WERE
......................................................................
DIRECTOR (BEGAN 3/2021)
2.00
.................
0.00
X
0
0
0
(16)
LUTZ HEGEMANN MD PHD
......................................................................
DIRECTOR (BEGAN 6/2021)
2.00
.................
0.00
X
0
0
0
(17)
NIKOLAJ JESTED GILBERT MSC
......................................................................
PRESIDENT AND CEO
39.00
.................
1.00
X
591,896
0
43,730
Form
990
(2021)
Form 990 (2021)
Page
8
Part VII
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
(continued)
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(F)
Estimated amount of other compensation from the organization and related organizations
(18)
JERRY KUO MBA
........................................................................
CHIEF OF STRGC. FIN. (UNTIL 1/4/21)
39.00
.......................
1.00
X
134,055
0
4,302
(19)
PHILIPPE GUINOT MBA
........................................................................
CHIEF OF BUSINESS, FIN. & OPERATIONS
1.00
.......................
39.00
X
0
316,221
25,825
(20)
DAVID C KASLOW MD
........................................................................
CHIEF EXECUTIVE-ESSENTIAL MEDICINES
39.00
.......................
1.00
X
408,184
0
67,963
(21)
JEFFREY D BERNSON MPH MPA
........................................................................
CHIEF EXECUTIVE-PROGRAM & INNOVATION
40.00
.......................
0.00
X
322,840
0
58,884
(22)
DAVID W FLEMING--SENIOR VP MD
........................................................................
OF PUBLIC HEALTH(UNTIL 2/11/21)
40.00
.......................
0.00
X
241,202
0
10,041
(23)
CARLA ANNE COSTA SANDINE
........................................................................
CHIEF OF EXTERNAL AFFAIRS
40.00
.......................
0.00
X
268,166
0
46,608
(24)
MOLLI M BARNES
........................................................................
CHIEF PEOPLE OFFICER
40.00
.......................
0.00
X
261,290
0
49,413
(25)
ERICA JANE SESSLE MPHIL MPH
........................................................................
CHIEF OF STAFF (UNTIL 10/1/21)
40.00
.......................
0.00
X
355,383
0
40,626
(26)
NANTHALILE C MUGALA MD MMED
........................................................................
CHIEF EXECUTIVE-AFRICA REGION
40.00
.......................
0.00
X
288,679
0
0
(27)
SABRINA L POWERS JD
........................................................................
GENERAL COUNSEL
40.00
.......................
0.00
X
265,189
0
44,732
(28)
TRAD M HATTON MA MHS
........................................................................
COUNTRY DIRECTOR
40.00
.......................
0.00
X
345,991
0
52,997
(29)
KIMBERLY GREEN PHD
........................................................................
DIRECTOR, PRIMARY HEALTH CARE
40.00
.......................
0.00
X
322,267
0
60,231
(30)
ASHLEY J BIRKETT PHD
........................................................................
GLOBAL HEAD, MALARIA VACCINES
40.00
.......................
0.00
X
330,205
0
59,071
(31)
BRUCE LAMONT INNIS MD FIDSA
........................................................................
GLOBAL HEAD, RESPIRATORY INFECTIONS & MATERNAL IMM
40.00
.......................
0.00
X
342,216
0
30,989
(32)
JOHN O KONZ PHD
........................................................................
GLOBAL HEAD, INT. PTFL. & FIN. MGMT.
40.00
.......................
0.00
X
330,414
0
64,894
(33)
ELAINE L GIBBONS CFA
........................................................................
FRMR VP-GLOBAL ENGMT. (LEFT 2020)
40.00
.......................
0.00
X
184,790
0
2,056
1b
Sub-Total
................
c
Total from continuation sheets to
Part VII
, Section A
....
d
Total (add lines 1b and 1c)
...........
4,992,767
316,221
662,362
2
Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization
354
Yes
No
3
Did the organization list any
former
officer, director or trustee, key employee, or highest compensated employee on line 1a?
If "Yes," complete Schedule J for such individual
..............
3
Yes
4
For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000?
If "Yes," complete Schedule J for such
individual
...........................
4
Yes
5
Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization?
If "Yes," complete Schedule J for such person
........
5
No
Section B. Independent Contractors
1
Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization’s tax year.
(A)
Name and business address
(B)
Description of services
(C)
Compensation
RANDSTAD INDIA PVT LTD
SUITE NO 001 002 COPIA
NEW DELHI
110025
IN
STAFFING SERVICES
1,796,178
SAFEGUARD WORLD INT'L
MOSS LANE EDWIN FODEN BUS CENTRE
SANDBACH
CW113AE
UK
GENERAL CONTRACTOR
1,322,299
UNIT4 BUSINESS SOFTWARE INC
3 BURLINGTON WOODS
BURLINGTON
,
MA
01803
SYSTEMS CONTRACTOR
729,988
PIVOTAL CONSULTING LLC
1631 15TH AVE W 118
SEATTLE
,
WA
98119
CONSULTING
600,556
GLOBALIZATION PARTNERS INC
175 FEDERAL ST 17TH FL
BOSTON
,
MA
02110
STAFFING SERVICES
464,096
2
Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization
41
Form
990
(2021)
Form 990 (2021)
Page
9
Part VIII
Statement of Revenue
Check if Schedule O contains a response or note to any line in this
Part VIII
.............
(A)
Total revenue
(B)
Related or
exempt
function
revenue
(C)
Unrelated
business
revenue
(D)
Revenue
excluded from
tax under sections
512 - 514
1a
Federated campaigns
..
1a
b
Membership dues
..
1b
c
Fundraising events
..
1c
d
Related organizations
1d
2,279,943
e
Government grants (contributions)
1e
113,800,820
f
All other contributions, gifts, grants, and similar amounts not included above
1f
216,988,196
g
Noncash contributions included in lines 1a - 1f:$
1g
3,097,897
h Total.
Add lines 1a-1f
.......
333,068,959
Business Code
2a
b
c
d
e
f
All other program service revenue.
g
Total.
Add lines 2a–2f
.....
3
Investment income (including dividends, interest, and other
similar amounts)
......
8,920,472
8,920,472
4
Income from investment of tax-exempt bond proceeds
5
Royalties
...........
(ii) Personal
(i) Real
6a
Gross rents
6a
b
Less: rental expenses
6b
c
Rental income or (loss)
6c
d
Net rental income or (loss)
.......
(ii) Other
(i) Securities
7a
Gross amount from sales of assets other than inventory
22,137
56,047,000
7a
b
Less: cost or other basis and sales expenses
169,653
55,614,599
7b
c
Gain or (loss)
-147,516
432,401
7c
d
Net gain or (loss)
.........
284,885
284,885
8a
Gross income from fundraising events (not including $
of contributions reported on line 1c).
See
Part IV
, line 18
....
8a
b
Less: direct expenses
...
8b
c
Net income or (loss) from fundraising events
..
9a
Gross income from gaming activities.
See
Part IV
, line 19
...
9a
b
Less: direct expenses
...
9b
c
Net income or (loss) from gaming activities
..
10a
Gross sales of inventory, less
returns and allowances
..
10a
b
Less: cost of goods sold
..
10b
c
Net income or (loss) from sales of inventory
..
Business Code
Miscellaneous Revenue
11a
OTHER
900099
804,482
804,482
b
REIMBURSEMENTS
900099
38,788
38,788
c
d
All other revenue
....
e
Total.
Add lines 11a–11d
......
843,270
12
Total revenue.
See instructions
.....
343,117,586
0
0
10,048,627
Form
990
(2021)
Form 990 (2021)
Page
10
Part IX
Statement of Functional Expenses
Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).
Check if Schedule O contains a response or note to any line in this
Part IX
..............
Do not include amounts reported on lines 6b,
7b, 8b, 9b, and 10b of
Part VIII
.
(A)
Total expenses
(B)
Program service
expenses
(C)
Management and
general expenses
(D)
Fundraising
expenses
1
Grants and other assistance to domestic organizations and domestic governments. See
Part IV
, line 21
....
24,971,209
24,971,209
2
Grants and other assistance to domestic individuals. See
Part IV
, line 22
...........
3
Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See
Part IV
, lines 15 and 16.
.............
50,990,746
50,990,746
4
Benefits paid to or for members
.......
5
Compensation of current officers, directors, trustees, and key employees
...........
3,503,184
304,810
3,198,374
6
Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)
.........
186,846
186,846
7
Other salaries and wages
........
98,900,832
84,542,681
12,401,955
1,956,196
8
Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)
....
10,846,071
9,740,836
866,213
239,022
9
Other employee benefits
.......
15,530,594
14,465,840
968,297
96,457
10
Payroll taxes
...........
6,439,800
5,787,905
592,796
59,099
11
Fees for services (non-employees):
a
Management
......
b
Legal
.........
1,361,906
689,129
669,780
2,997
c
Accounting
...........
941,141
234,102
707,039
d
Lobbying
...........
e
Professional fundraising services.
See
Part IV
, line 17
f
Investment management fees
......
335,619
335,619
g
Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)
21,356,638
16,798,933
4,206,724
350,981
12
Advertising and promotion
....
259,645
204,097
5,771
49,777
13
Office expenses
.......
8,500,810
8,062,238
346,509
92,063
14
Information technology
......
7,759,274
6,314,353
1,383,166
61,755
15
Royalties
..
40,100
40,100
16
Occupancy
...........
13,663,995
254,156
13,408,822
1,017
17
Travel
............
8,854,734
8,756,823
97,562
349
18
Payments of travel or entertainment expenses for any federal, state, or local public officials
.
19
Conferences, conventions, and meetings
....
8,927,984
8,672,961
254,256
767
20
Interest
...........
14
14
21
Payments to affiliates
.......
22
Depreciation, depletion, and amortization
..
2,442,094
9,302
2,432,792
23
Insurance
...
760,860
460,013
300,847
24
Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a
SUBCONTRACTORS
32,708,095
32,708,095
b
EQUIP RENT & MAINT
11,123,049
10,973,340
149,709
c
DIRECT AID TO BENEF.
986,176
986,176
d
FACILITIES ALLOC
0
13,860,521
-14,219,377
358,856
e
All other expenses
3,953,213
1,305,720
249,627
2,397,866
25
Total functional expenses.
Add lines 1 through 24e
335,344,629
301,134,100
28,543,327
5,667,202
26
Joint costs.
Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation.
Check here
if following SOP 98-2 (ASC 958-720).
Form
990
(2021)
Form 990 (2021)
Page
11
Part X
Balance Sheet
Check if Schedule O contains a response or note to any line in this
Part IX
..............
(A)
Beginning of year
(B)
End of year
1
Cash–non-interest-bearing
........
7,194,550
1
12,911,863
2
Savings and temporary cash investments
.........
9,719,000
2
10,006,728
3
Pledges and grants receivable, net
......
39,742,632
3
38,296,068
4
Accounts receivable, net
.............
258,036
4
555,337
5
Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons
.......
5
6
Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)
...
6
7
Notes and loans receivable, net
...........
7
8
Inventories for sale or use
............
8
9
Prepaid expenses and deferred charges
......
7,008,112
9
7,454,031
10a
Land, buildings, and equipment: cost or other basis. Complete
Part VI
of Schedule D
10a
37,891,859
b
Less: accumulated depreciation
10b
30,772,154
8,413,303
10c
7,119,705
11
Investments—publicly traded securities
.
211,220,570
11
230,729,600
12
Investments—other securities. See
Part IV
, line 11
.....
12
13
Investments—program-related. See
Part IV
, line 11
..
13
14
Intangible assets
...............
14
15
Other assets. See
Part IV
, line 11
...........
15
16
Total assets.
Add lines 1 through 15 (must equal line 33)
...
283,556,203
16
307,073,332
17
Accounts payable and accrued expenses
.....
234,982,056
17
253,115,813
18
Grants payable
...
18
19
Deferred revenue
.........
19
20
Tax-exempt bond liabilities
.........
20
21
Escrow or custodial account liability.
Complete
Part IV
of Schedule D
21
22
Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons
.........
22
23
Secured mortgages and notes payable to unrelated third parties
..
23
24
Unsecured notes and loans payable to unrelated third parties
..
24
25
Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24).
Complete
Part X
of Schedule D
25
26
Total liabilities.
Add lines 17 through 25
..
234,982,056
26
253,115,813
Organizations that follow FASB ASC 958,
check here
and complete lines 27, 28, 32, and 33.
27
Net assets without donor restrictions
..........
21,554,594
27
20,653,709
28
Net assets with donor restrictions
...........
27,019,553
28
33,303,810
Organizations that do not follow FASB ASC 958,
check here
and complete lines 29 through 33.
29
Capital stock or trust principal, or current funds
.....
29
30
Paid-in or capital surplus, or land, building or equipment fund
...
30
31
Retained earnings, endowment, accumulated income, or other funds
31
32
Total net assets or fund balances
...........
48,574,147
32
53,957,519
33
Total liabilities and net assets/fund balances
........
283,556,203
33
307,073,332
Form
990
(2021)
Form 990 (2021)
Page
12
Part XI
Reconcilliation of Net Assets
Check if Schedule O contains a response or note to any line in this
Part XI
..............
1
Total revenue (must equal
Part VIII
, column (A), line 12)
............
1
343,117,586
2
Total expenses (must equal
Part IX
, column (A), line 25)
............
2
335,344,629
3
Revenue less expenses. Subtract line 2 from line 1
..............
3
7,772,957
4
Net assets or fund balances at beginning of year (must equal
Part X
, line 32, column (A))
..
4
48,574,147
5
Net unrealized gains (losses) on investments
...............
5
-2,389,585
6
Donated services and use of facilities
.................
6
7
Investment expenses
.....................
7
8
Prior period adjustments
.....................
8
9
Other changes in net assets or fund balances (explain in Schedule O)
........
9
0
10
Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal
Part X
, line 32, column (B))
10
53,957,519
Part XII
Financial Statements and Reporting
Check if Schedule O contains a response or note to any line in this
Part XII
.............
Yes
No
1
Accounting method used to prepare the Form 990:
Cash
Accrual
Other
If the organization changed its method of accounting from a prior year or checked "Other," explain on
Schedule O.
2a
Were the organization’s financial statements compiled or reviewed by an independent accountant?
2a
No
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
b
Were the organization’s financial statements audited by an independent accountant?
2b
Yes
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
c
If "Yes," to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight
of the audit, review, or compilation of its financial statements and selection of an independent accountant?
2c
Yes
If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.
3a
As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?
3a
Yes
b
If "Yes," did the organization undergo the required audit or audits?
If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits.
3b
Yes
Form
990
(2021)
Form 990 (2021)
Additional Data
Software ID:
Software Version:
Form 990, Special Condition Description:
Special Condition Description